TY - JOUR
T1 - Enterohaemorrhagic Escherichia coli in human medicine
AU - Karch, Helge
AU - Tarr, Phillip I.
AU - Bielaszewska, Martina
N1 - Funding Information:
The research of Dr. Helge Karch on EHEC infections has been supported by the Bundesministerium für Bildung und Forschung (BMBF) Verbundsprojekt, Forschungsnetzwerk “Emerging foodborne pathogens in Germany”, grant FKZ 01 KI 9903, by BMBF Project Network of Competence Pathogenomics Alliance “Functional Genomic research on enterohaemorrhagic Escherichia coli”, grant BD 119523, and by the Deutsche Forschungsgemeinschaft, grant FKZ KA 717/2-4. Research from the group of Dr. Tarr presented in this communication has been supported by grants from the NIH (R01 AI47499 and DK 52081) and Centers for Disease Control and Prevention (CCU015040). We thank Dr. Helmut Tschäpe (Robert Koch-Institut, Wernigerode) for serotyping of the EHEC isolates from Germany and stimulating discussions.
PY - 2005/10/5
Y1 - 2005/10/5
N2 - Enterohaemorrhagic Escherichia coli (EHEC) are the pathogenic subgroup of Shiga toxin (Stx)-producing E. coli. EHEC can cause non-bloody and bloody diarrhoea, and the haemolytic uraemic syndrome (HUS). HUS is a major cause of acute renal failure in children. E. coli O157:H7 is the predominant, but far from being the only, serotype that can cause HUS. The cascade leading from gastrointestinal infection to renal impairment is complex, with the microvascular endothelium being the major histopathological target. EHEC also produce non-Stx molecules, such as cytolethal distending toxin, which can contribute to the endothelial or vascular injury. Because there are no specific therapies for EHEC infections, efficient reservoir and human preventive strategies are important areas of ongoing investigations. This review will focus on the microbiology, epidemiology, and pathophysiology of EHEC-associated diseases, and illustrate future challenges and opportunities for their control.
AB - Enterohaemorrhagic Escherichia coli (EHEC) are the pathogenic subgroup of Shiga toxin (Stx)-producing E. coli. EHEC can cause non-bloody and bloody diarrhoea, and the haemolytic uraemic syndrome (HUS). HUS is a major cause of acute renal failure in children. E. coli O157:H7 is the predominant, but far from being the only, serotype that can cause HUS. The cascade leading from gastrointestinal infection to renal impairment is complex, with the microvascular endothelium being the major histopathological target. EHEC also produce non-Stx molecules, such as cytolethal distending toxin, which can contribute to the endothelial or vascular injury. Because there are no specific therapies for EHEC infections, efficient reservoir and human preventive strategies are important areas of ongoing investigations. This review will focus on the microbiology, epidemiology, and pathophysiology of EHEC-associated diseases, and illustrate future challenges and opportunities for their control.
KW - Diarrhoea
KW - EHEC O157:H7
KW - EHEC non-O157
KW - Enterohaemorrhagic Escherichia coli
KW - Haemolytic uraemic syndrome
UR - https://www.scopus.com/pages/publications/24044469996
U2 - 10.1016/j.ijmm.2005.06.009
DO - 10.1016/j.ijmm.2005.06.009
M3 - Review article
C2 - 16238016
AN - SCOPUS:24044469996
SN - 1438-4221
VL - 295
SP - 405
EP - 418
JO - International Journal of Medical Microbiology
JF - International Journal of Medical Microbiology
IS - 6-7
ER -